BRPI0610322B8 - inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica - Google Patents

inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica

Info

Publication number
BRPI0610322B8
BRPI0610322B8 BRPI0610322A BRPI0610322A BRPI0610322B8 BR PI0610322 B8 BRPI0610322 B8 BR PI0610322B8 BR PI0610322 A BRPI0610322 A BR PI0610322A BR PI0610322 A BRPI0610322 A BR PI0610322A BR PI0610322 B8 BRPI0610322 B8 BR PI0610322B8
Authority
BR
Brazil
Prior art keywords
receptor signaling
hgf
pharmaceutical composition
receptor
signaling inhibitors
Prior art date
Application number
BRPI0610322A
Other languages
English (en)
Inventor
Wahhab Amal
Vaisburg Arkadii
Raeppel Franck
Gaudette Frederic
Zhan Lijie
Isakovic Ljubomir
Granger Marie-Claude
Mannion Michael
Zhou Nancy
Bernstein Naomy
Mario Saavedra Oscar
Deziel Robert
Raeppel Stephane
William Claridge Stephen
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of BRPI0610322A2 publication Critical patent/BRPI0610322A2/pt
Publication of BRPI0610322B1 publication Critical patent/BRPI0610322B1/pt
Publication of BRPI0610322B8 publication Critical patent/BRPI0610322B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

inibidores de sinalização de receptor de vegf e receptor de hgf. a presente invenção refere-se à inibição de sinalização de receptor de vegf e sinalização de receptor de hgf. a invenção fornece compostos e métodos para inibição da sinalização de receptor de vegf e sinalização de receptor de hgf. a invenção também fornece composições e métodos para tratar doenças e condições proliferativas celulares.
BRPI0610322A 2005-05-20 2006-05-19 inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica BRPI0610322B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68303605P 2005-05-20 2005-05-20
US60/683,036 2005-05-20
US75490205P 2005-12-29 2005-12-29
US60/754,902 2005-12-29
US78505406P 2006-03-22 2006-03-22
US60/785,054 2006-03-22
PCT/IB2006/004306 WO2008041053A2 (en) 2005-05-20 2006-05-19 Inhibitors of vegf receptor and hgf receptor signaling

Publications (3)

Publication Number Publication Date
BRPI0610322A2 BRPI0610322A2 (pt) 2010-06-15
BRPI0610322B1 BRPI0610322B1 (pt) 2020-12-01
BRPI0610322B8 true BRPI0610322B8 (pt) 2021-05-25

Family

ID=39190471

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610322A BRPI0610322B8 (pt) 2005-05-20 2006-05-19 inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica

Country Status (13)

Country Link
US (2) US8093264B2 (pt)
EP (1) EP1957498B1 (pt)
JP (1) JP5148499B2 (pt)
KR (1) KR101378716B1 (pt)
CN (1) CN101796055B (pt)
AU (1) AU2006343808B2 (pt)
BR (1) BRPI0610322B8 (pt)
CA (1) CA2611370C (pt)
ES (1) ES2623221T3 (pt)
IL (1) IL187484A (pt)
MX (1) MX2007014616A (pt)
NZ (1) NZ564283A (pt)
WO (1) WO2008041053A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
RU2007107167A (ru) * 2004-07-30 2008-09-10 Метилджин, Инк. (Ca) Ингибиторы передачи сигнала рецептора vegf и рецептора hgf
CN101248080B (zh) * 2005-05-20 2012-09-05 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
PE20070619A1 (es) * 2005-09-27 2007-07-02 Wyeth Corp TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
WO2008063202A2 (en) * 2006-01-30 2008-05-29 Array Biopharma Inc. Heterobicyclic thiophene compounds for the treatment of cancer
CA2645137A1 (en) * 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
EA200802118A1 (ru) 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2009026701A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
NZ589336A (en) * 2008-03-05 2011-12-22 Methylgene Inc Pyridine derivatives as inhibitors of protein tyrosine kinase activity
WO2010023181A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
US8278331B2 (en) * 2008-10-29 2012-10-02 Deciphera Pharmaceuticals, Llc N-acyl ureas exhibiting anti-cancer and anti-proliferative activities
WO2010111063A1 (en) * 2009-03-21 2010-09-30 Ning Xi Amino ester derivatives, salts thereof and methods of use
WO2011082273A2 (en) * 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2547905T3 (es) 2010-02-26 2015-10-09 Evotec International Gmbh 4-[Cicloalquiloxi(hetero)arilamino]-tieno[2,3-d]pirimidinas que tienen actividad inhibidora de la Mnk1/Mnk2 para composiciones farmacéuticas
MX2012009851A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
CN101863911A (zh) * 2010-04-13 2010-10-20 艾琪康医药科技（上海）有限公司 一种1-r1-3,4-脱氢-3或4-r6-哌啶的制备方法
AU2011241422B2 (en) * 2010-04-16 2015-05-07 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130225581A1 (en) 2010-07-16 2013-08-29 Kyowa Hakko Kirin Co., Ltd Nitrogen-containing aromatic heterocyclic derivative
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
JP5707518B2 (ja) 2011-02-28 2015-04-30 カリトル サイエンシズ， エルエルシー 置換型キノリン化合物及び使用方法
JP6218848B2 (ja) * 2012-11-20 2017-10-25 プロキナーゼ ゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのチオエーテル誘導体
MD20160112A2 (ro) 2014-04-25 2017-06-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
CN105348213A (zh) * 2015-09-22 2016-02-24 武汉理工大学 β-氟烷基-β-氨基酸类化合物的制备方法
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
KR20190035925A (ko) 2016-08-24 2019-04-03 아르퀼 인코포레이티드 아미노-피롤로피리미디논 화합물 및 이의 사용 방법
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
CN110423218A (zh) * 2019-08-09 2019-11-08 新乡双鹭药业有限公司 一种苹果酸卡博替尼合成中杂质的制备方法
CN113336768B (zh) * 2020-02-18 2022-08-19 深圳海王医药科技研究院有限公司 一种多靶点酪氨酸激酶抑制剂
CN114957136A (zh) * 2021-02-24 2022-08-30 南京科默生物医药有限公司 一种用作vegfr抑制剂的抗肿瘤化合物及其用途
CN115215803B (zh) * 2022-09-19 2022-12-30 苏州美诺医药科技有限公司 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100392057B1 (ko) 1993-11-30 2003-10-30 맥길 유니버시티 세포의 CpG 디뉴클레오티드 내의 시토신의 메틸화를 감소하는 방법
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
WO2000071703A2 (en) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU783504C (en) 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
WO2003006652A2 (en) 2000-03-24 2003-01-23 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
EP1287001B1 (en) 2000-06-06 2004-09-29 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
NZ525324A (en) * 2000-10-20 2005-03-24 Eisai Co Ltd Nitrogenous aromatic ring compounds
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
US7425564B2 (en) * 2001-06-22 2008-09-16 Kirin Beer Kabushiki Kaisha Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus prolifertor receptor and medicinal composition containing the same
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
BR0212510A (pt) 2001-09-14 2004-08-24 Methylgene Inc Inibidor de histona desacetilase, composto e composição
BR0308162A (pt) 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
AU2003273701A1 (en) 2002-10-17 2004-05-04 Methylgene Inc. Inhibitors of histone deacetylase
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
ATE412655T1 (de) * 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
CA2537812C (en) * 2003-09-26 2013-01-22 Exelixis, Inc. C-met modulators and method of use
US7581674B2 (en) 2003-11-21 2009-09-01 Charles Cohen Financial transaction system and method
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
JP5319113B2 (ja) 2004-03-26 2013-10-16 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AU2005270068B2 (en) * 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
KR20070057792A (ko) 2004-07-16 2007-06-07 선에시스 파마슈티컬스 인코포레이티드 오로라 키나아제 저해물질로서 유용한 티에노피리미딘
RU2007107167A (ru) * 2004-07-30 2008-09-10 Метилджин, Инк. (Ca) Ингибиторы передачи сигнала рецептора vegf и рецептора hgf
US7647492B2 (en) 2004-09-15 2010-01-12 Check Point Software Technologies Inc. Architecture for routing and IPSec integration
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
WO2008063202A2 (en) 2006-01-30 2008-05-29 Array Biopharma Inc. Heterobicyclic thiophene compounds for the treatment of cancer
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
US20070004675A1 (en) 2007-01-04
CA2611370A1 (en) 2006-11-20
ES2623221T3 (es) 2017-07-10
KR20080059112A (ko) 2008-06-26
KR101378716B1 (ko) 2014-04-10
BRPI0610322B1 (pt) 2020-12-01
CN101796055B (zh) 2013-09-04
US8329726B2 (en) 2012-12-11
IL187484A0 (en) 2011-08-01
CA2611370C (en) 2014-11-25
IL187484A (en) 2014-04-30
NZ564283A (en) 2011-07-29
US8093264B2 (en) 2012-01-10
BRPI0610322A2 (pt) 2010-06-15
EP1957498B1 (en) 2017-02-15
AU2006343808B2 (en) 2012-03-29
CN101796055A (zh) 2010-08-04
AU2006343808A1 (en) 2008-04-10
JP5148499B2 (ja) 2013-02-20
EP1957498A2 (en) 2008-08-20
WO2008041053A3 (en) 2009-12-23
WO2008041053A2 (en) 2008-04-10
MX2007014616A (es) 2009-08-12
US20120083482A1 (en) 2012-04-05
JP2009504804A (ja) 2009-02-05
EP1957498A4 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
BRPI0610322B8 (pt) inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
BRPI0513982A (pt) inibidores de sinalização de receptor de vegf e receptor de hgf
TN2009000255A1 (en) Quinazolines for pdk1 inhibition
BR112013011441A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
WO2007054831A3 (en) Inhibitors of vegf receptor and hgf receptor signaling
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
CL2008003339A1 (es) Compuestos derivados de pirimidin-2(1h)-ona, inhibidores de la 11b-hidroxiesteroide deshidrogenasa 1; composicion farmaceutica, util para el tratamiento de enfermedades tales como obesidad, hipertension e hiperlipidemia.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DOP2012000006A (es) Agonista de gpr119
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
MX2009003981A (es) Agentes moduladores del receptor de calcio.
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: APRESENTE O DEPOSITANTE COPIA DA FOLHA DE ROSTO DA PUBLICACAO INTERNACIONAL DO PEDIDO, CONFORME O DISPOSTO NO ITEM 9.3 DO AN NO 128/1997.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF